Loss of response to melatonin treatment is associated with slow melatonin metabolism.
High nighttime saliva melatonin may explain lost sleep benefit in adults with ID—lower the dose, don’t raise it.
01Research in Context
What this study did
Doctors followed six adults with intellectual disability who had used melatonin for sleep.
They checked saliva four hours after the nightly pill to see how fast the drug left the body.
What they found
The three people whose sleep got worse still had lots of melatonin in saliva at 4 a.m.
When the team cut the dose, sleep improved again.
How this fits with other research
Bellon-Harn et al. (2020) saw that sleep trouble raises anxiety in older Irish adults with ID, but they did not test melatonin.
Lundqvist (2013) found sleep issues flag risk for behavior problems in Swedish adults with ID, again without drug data.
D'Souza et al. (2020) show sleep is already off track in toddlers with Down, fragile X, and Williams syndromes, pointing to early screening.
Together the papers say: check sleep in every age band, and if melatonin fails, look at metabolism before blaming the client.
Why it matters
You can run a quick four-hour saliva check when melatonin ‘stops working.’ If levels are high, drop the dose instead of raising it. This simple switch can restore sleep without new meds or side effects.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Ask the caregiver to collect saliva four hours after the pill; if the lab report shows high melatonin, cut the dose in half and track sleep for one week.
02At a glance
03Original abstract
BACKGROUND: In some of our patients with intellectual disability (ID) and sleep problems, the initial good response to melatonin disappeared within a few weeks after starting treatment, while the good response returned only after considerable dose reduction. The cause for this loss of response to melatonin is yet unknown. We hypothesise that this loss of response is associated with slow melatonin metabolism. METHOD: In this study, we determined melatonin clearance in two female (aged 61 and 6 years) and one male (aged 3 years) patients who had chronic insomnia, late melatonin onset and mild ID, and whose sleep quality worsened a few weeks after initial good response to melatonin treatment, suggesting melatonin tolerance. After a 3-week washout period, patients received melatonin 1.0, 0.5 or 0.1 mg, respectively. Salivary melatonin level was measured just before melatonin administration, and 2 and 4 h thereafter. After this melatonin clearance test, melatonin treatment was resumed with a considerably lower dose. RESULTS: In all patients melatonin concentrations remained >50 pg/mL at 2 and 4 h after melatonin administration. After resuming melatonin treatment sleep problems disappeared. The same procedure was followed in three patients who did not show loss of response to melatonin after 6 months of treatment. In all patients in the control group melatonin concentrations decreased between 2 and 4 h after melatonin administration with a mean of 83%. CONCLUSION: We hypothesise that loss of response to melatonin treatment can be caused by slow metabolisation of exogenous melatonin. As melatonin is metabolised in the liver almost exclusively by cytochrome P450 enzyme CYP1A2, this slow melatonin metabolism is probably due to decreased activity/inducibility of CYP1A2. In patients with loss of response to melatonin, a melatonin clearance test should be considered and a considerably dose reduction is advised.
Journal of intellectual disability research : JIDR, 2010 · doi:10.1111/j.1365-2788.2010.01283.x